dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
Our semi-annual study of digital health apps in diabetes, known as “DHx” (Digital Health Experience), finds broad variation in patient satisfaction.
We're proud to share Evelyn Cox’s EASD 2022 abstract revealing mental-health disparities among Europeans with diabetes by nationality, gender, and age.
Our T2 Insulin Insights is a semi-annual Research Service that explores the lived experience of people with type 2 diabetes who take insulin.
A national dQ&A survey of over 5,000 people with diabetes found wide variation in grocery store quality, with Aldi, Publix, Costco, H-E-B, and Hy-Vee rated highest.
We are excited to announce dQ&A’s new syndicated qualitative research service, First Look Insights.
This survey shows COVID-19 booster rates are higher in U.S. adults with diabetes than the general population, but vary by race, income, and location.
We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.
ADA and dQ&A survey results reveal that COVID fears kept one in five people with diabetes away from the doctor during the pandemic.
